Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
KD-496
i
Other names:
KD-496, NKG2D/CLDN18.2 CAR-T
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
KAEDI
Drug class:
CLDN18.2-targeted CAR-T immunotherapy, NKG2D-targeted CAR-T immunotherapy
Related drugs:
‹
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IM92 (0)
IMC002 (0)
IMC008 (0)
KD-182 (0)
LB1908 (0)
LY011 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
CD19/NKG2DL CAR-T Therapeutic (0)
CYAD-01 (0)
KD-025 CAR T-cells (0)
NKG2D CAR T-cells (0)
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IM92 (0)
IMC002 (0)
IMC008 (0)
KD-182 (0)
LB1908 (0)
LY011 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
CD19/NKG2DL CAR-T Therapeutic (0)
CYAD-01 (0)
KD-025 CAR T-cells (0)
NKG2D CAR T-cells (0)
›
Associations
News
Trials
Filter by
Latest
1year
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Peking University
1 year ago
New P1 trial • Metastases
|
KD-496
2years
NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, jianming xu
2 years ago
New P1 trial • Metastases
|
CLDN18 (Claudin 18)
|
KD-496
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login